Ge Healthcare Technologies Inc - GEHC STOCK NEWS

GE HealthCare has unveiled the new Pristina Via mammography system at RSNA 2024, designed to enhance breast screening efficiency amid growing technologist shortages. The system features zero-click acquisition, faster image-to-image cycle time, and vendor-neutral prior image comparison.

Developed through extensive collaboration with technologists, including 250 interviews and observations, the system addresses the challenge of increasing vacancy rates (18% in 2024) while maintaining steady mammogram demand. Pristina Via offers the lowest radiation dose among major mammography systems and demonstrates 99% uptime under service contracts.

GE HealthCare (Nasdaq: GEHC) has announced its management team's participation in two major upcoming investor conferences. The first presentation will be at the Nasdaq Investor Conference in London on December 10, 2024, at 11:00 am GMT. The second presentation will take place at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025, at 4:15 pm CT. Both events will be accessible via webcast through GE HealthCare's investor relations website.

GE HealthCare has enhanced its OEC 3D mobile CBCT C-arm portfolio with new features for endoscopic bronchoscopy procedures. The key additions include the OEC 3D Lung Suite, which offers augmented fluoroscopy overlay and adjustable motorized 3D scanning, and expanded OEC Open interface compatibility with Intuitive's Ion® Endoluminal Robotic Bronchoscopy System. These innovations aim to improve visualization of airways and streamline workflow during bronchoscopy procedures, helping clinicians better diagnose and biopsy lung lesions despite challenges like CT to body divergence.

GE HealthCare hosted its 2024 Investor Day at Nasdaq MarketSite, highlighting its precision care strategy and financial progress. The company announced a 17% increase in quarterly dividend to $0.035 per share. GE HealthCare reiterated its 2024 outlook with organic revenue growth of 1-2% and presented medium-term targets for 2026-2028, including 4-6% organic revenue growth and high-teens to 20%+ adjusted EBIT margin. The company emphasized its focus on innovation, AI strategy, and radiopharmaceutical growth opportunities across its segments.

GE HealthCare announced results from the COSMOS pilot study evaluating their Portrait Mobile monitoring solution in post-surgical settings. The two-phase, 250-patient study showed that 82% of alarms were considered informative or useful by clinicians, with an average of less than three alarms per patient per day. The system demonstrated effectiveness in encouraging clinical intervention while reducing alarm fatigue. Notable outcomes include approximately 25% reduction in vital sign abnormalities and 60% more oxygen therapy interventions in monitored patients compared to those with standard intermittent monitoring. The study highlights Portrait Mobile's potential to enable early detection of patient deterioration and timely clinical intervention in medical-surgical units.

GE HealthCare has received FDA 510(k) clearance for its SIGNA™ MAGNUS, a 3.0T head-only MRI scanner designed for advanced neuroimaging. The system features an innovative asymmetrical head-only gradient coil design that achieves higher gradient performance with reduced inner diameter. The technology delivers gradient amplitude and slew rate superior to conventional whole-body MRI systems, with performance levels of 300 mT/m and 750 T/m/s. The system enables shorter scan times and enhanced spatial resolution while maintaining the same power requirements as the SIGNA Premier 3.0T system. Four investigational MAGNUS systems have already been installed at major medical centers.

GE HealthCare (Nasdaq: GEHC) has announced a new initiative with AMN Healthcare to address the critical shortage of radiologic technologists in healthcare. The shortage is attributed to clinician burnout, COVID-19 impacts, and demand outpacing the number of trained professionals, with 42% of clinicians considering leaving healthcare. The collaboration combines GE HealthCare's technology training expertise across multiple imaging modalities with AMN Healthcare's workforce solutions to help healthcare providers meet staffing needs. The initiative aims to develop capacity and train the next generation of rad techs across both hospital and outpatient settings.

GE HealthCare (GEHC) and RadNet's DeepHealth announced a strategic collaboration to advance AI in medical imaging. The partnership will combine GE HealthCare's imaging expertise with RadNet's DeepHealth AI solutions to create SmartTechnology™ solutions. Their first initiative integrates DeepHealth's AI-powered SmartMammo™ with GE's Senographe Pristina™ mammography system to enhance breast cancer screening. The collaboration includes Smart Alerts, aimed at enabling rapid AI processing for potentially suspicious lesions. GE HealthCare will distribute SmartMammo and other DeepHealth solutions in the United States as part of their imaging technologies portfolio.

GE HealthCare Technologies (Nasdaq: GEHC) has announced the pricing of a secondary public offering of 13,281,302 shares of its common stock. The company will not receive any proceeds from the sale, as GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank. Following this debt-for-equity exchange, Morgan Stanley & Co. will sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers. The offering is expected to close on November 12, 2024, subject to customary conditions.